[go: up one dir, main page]

PL3315131T3 - Środek terapeutyczny w zwłóknieniu - Google Patents

Środek terapeutyczny w zwłóknieniu

Info

Publication number
PL3315131T3
PL3315131T3 PL16814513.4T PL16814513T PL3315131T3 PL 3315131 T3 PL3315131 T3 PL 3315131T3 PL 16814513 T PL16814513 T PL 16814513T PL 3315131 T3 PL3315131 T3 PL 3315131T3
Authority
PL
Poland
Prior art keywords
fibrosis
therapeutic agent
therapeutic
agent
Prior art date
Application number
PL16814513.4T
Other languages
English (en)
Inventor
Akio Fujioka
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3315131T3 publication Critical patent/PL3315131T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
PL16814513.4T 2015-06-25 2016-06-24 Środek terapeutyczny w zwłóknieniu PL3315131T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015127788 2015-06-25
PCT/JP2016/068902 WO2016208744A1 (ja) 2015-06-25 2016-06-24 線維症治療剤

Publications (1)

Publication Number Publication Date
PL3315131T3 true PL3315131T3 (pl) 2022-12-12

Family

ID=57585165

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16814513.4T PL3315131T3 (pl) 2015-06-25 2016-06-24 Środek terapeutyczny w zwłóknieniu

Country Status (20)

Country Link
US (4) US10449189B2 (pl)
EP (2) EP3315131B1 (pl)
JP (3) JP6974167B2 (pl)
KR (1) KR102647942B1 (pl)
CN (2) CN107708697B (pl)
AU (1) AU2016284531B2 (pl)
BR (1) BR112017028137B1 (pl)
CA (1) CA2990791A1 (pl)
DK (1) DK3315131T3 (pl)
ES (1) ES2928684T3 (pl)
HU (1) HUE060732T2 (pl)
MA (1) MA42266A (pl)
MX (2) MX381792B (pl)
MY (1) MY191219A (pl)
PH (1) PH12017502322B1 (pl)
PL (1) PL3315131T3 (pl)
PT (1) PT3315131T (pl)
RU (1) RU2729630C2 (pl)
SG (2) SG10201912684TA (pl)
WO (1) WO2016208744A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139608A1 (en) 2006-03-14 2007-12-06 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
US12152246B2 (en) 2006-03-14 2024-11-26 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
PT3583943T (pt) 2017-02-15 2024-10-15 Taiho Pharmaceutical Co Ltd Composição farmacêutica
JP7074760B2 (ja) 2017-09-08 2022-05-24 大鵬薬品工業株式会社 抗腫瘍剤及び抗腫瘍効果増強剤
WO2020059744A1 (ja) 2018-09-18 2020-03-26 大鵬薬品工業株式会社 アシルチオウレア化合物とアビラテロンの併用療法
TWI872203B (zh) * 2020-02-14 2025-02-11 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313777T3 (es) 1998-04-28 2009-03-01 Toshikazu Nakamura Inhibidores de la neovascularizacion.
JP2003238592A (ja) 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
MX2007015679A (es) 2005-06-30 2008-02-21 Amgen Inc Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer.
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
CN101360748B (zh) * 2005-11-30 2012-05-30 沃泰克斯药物股份有限公司 c-MET抑制剂及其应用
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
WO2009053737A2 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
SI2287155T1 (sl) 2008-04-10 2013-10-30 Taiho Pharmaceutical Co., Ltd. Aciltiosečninska spojina ali njena sol in njena uporaba
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
BR112012019302B1 (pt) * 2010-02-03 2022-06-21 Incyte Holdings Corporation Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula
EA025281B9 (ru) 2010-05-17 2017-08-31 Инкозен Терапьютикс Пвт. Лтд. СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
RU2494470C1 (ru) * 2012-04-04 2013-09-27 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") Способ лечения фиброза легких
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis

Also Published As

Publication number Publication date
BR112017028137A2 (pt) 2018-08-28
JPWO2016208744A1 (ja) 2018-04-12
KR20180021682A (ko) 2018-03-05
US10695340B2 (en) 2020-06-30
PT3315131T (pt) 2022-10-26
HK1245639A1 (zh) 2018-08-31
MY191219A (en) 2022-06-09
SG10201912684TA (en) 2020-03-30
DK3315131T3 (da) 2022-11-14
US20180289690A1 (en) 2018-10-11
US10449189B2 (en) 2019-10-22
CN107708697B (zh) 2021-02-09
US11191759B2 (en) 2021-12-07
EP3973962A1 (en) 2022-03-30
HUE060732T2 (hu) 2023-04-28
AU2016284531A1 (en) 2017-11-30
JP2022009994A (ja) 2022-01-14
RU2017145271A (ru) 2019-07-25
RU2017145271A3 (pl) 2019-12-02
MA42266A (fr) 2018-05-02
JP2023076632A (ja) 2023-06-01
EP3315131A1 (en) 2018-05-02
US20200297716A1 (en) 2020-09-24
JP7258985B2 (ja) 2023-04-17
EP3315131A4 (en) 2019-02-27
MX381792B (es) 2025-03-13
US20200009128A1 (en) 2020-01-09
SG11201709260TA (en) 2018-01-30
MX2020012989A (es) 2021-02-16
CA2990791A1 (en) 2016-12-29
US20220047572A1 (en) 2022-02-17
JP6974167B2 (ja) 2021-12-01
PH12017502322B1 (en) 2023-08-30
PH12017502322A1 (en) 2018-06-25
BR112017028137B1 (pt) 2023-04-04
WO2016208744A1 (ja) 2016-12-29
US11690838B2 (en) 2023-07-04
MX2017016774A (es) 2018-05-14
CN107708697A (zh) 2018-02-16
RU2729630C2 (ru) 2020-08-11
KR102647942B1 (ko) 2024-03-14
JP7498827B2 (ja) 2024-06-12
EP3315131B1 (en) 2022-09-14
AU2016284531B2 (en) 2020-06-04
ES2928684T3 (es) 2022-11-21
CN112716952A (zh) 2021-04-30

Similar Documents

Publication Publication Date Title
IL250685A0 (en) Medicinal substance induces cytotoxicity
SG10201912416QA (en) Therapeutic agents
IL266530A (en) Fibrosis treatment
GB201509893D0 (en) Therapeutic agents
GB201517263D0 (en) Therapeutic agents
GB201410816D0 (en) Therapeutic agents
GB201603104D0 (en) Therapeutic agents
SG10201912684TA (en) Therapeutic agent for fibrosis
GB201509885D0 (en) Therapeutic agents
GB201502412D0 (en) Therapeutic use
GB201410817D0 (en) Therapeutic agents
IL253617A0 (en) Snekribirock for the treatment of leprosy
GB201410815D0 (en) Therapeutic agents
GB201509888D0 (en) Therapeutic agents
IL272271A (en) A therapeutic agent for fibrosis
IL250160A0 (en) medicinal substance
GB201513299D0 (en) Therapeutic agents
GB201521767D0 (en) Therapeutic agents
GB201517264D0 (en) Therapeutic agents
SG11201705915VA (en) Therapeutic agent for ischemic diseases
SG11201700059WA (en) Therapeutic agent for keratoconjunctive disorder
GB201506786D0 (en) Therapeutic use
GB201616563D0 (en) Therapeutic agents
GB201911521D0 (en) Therapeutic agent
GB201516109D0 (en) Therapeutic agent